SAT0214 CLINICAL FEATURES OF ANEURYSMAL BEHÇET DISEASE
Authors: Berkan Armagan, Ertuğrul Çağri Bölek, Alper Sari, Gözde Kübra Yardimci, Bayram Farisoğullari, Emre Bilgin, Fatma Gonca Eldem, Levent Kiliç, Omer Karadag, Bora Peynircioğlu, Barbaros Erhan Çil, Metin Demircin, Ali Akdoğan, Şule Apraş Bilgen, Ali İhsan Ertenli, Sedat Kiraz, Umut Kalyoncu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Arterial aneurysmatic lesions are one of the unique features of Behçet's disease (BD). However, it is difficult to determine which BD patients will develop an aneurysm. <h3>Objectives:</h3> In this study, we aimed to determine the differences between BD patients with and without an arterial aneurysm. <h3>Methods:</h3> Data of the 23 BD patients with an arterial aneurysm was published as an abstract in 2013 (1). We retrospectively reviewed the medical records of 441 patients with BD according to International Study Group (ISG) criteria between January 2013 and June 2018. Totally, we determined 45 BD patients with an arterial aneurysm. Six patients with isolated carotid and/or cranial arterial aneurysms who were followed by other clinics excluded from the analysis. Overall, 39 BD patients with an extracranial and extra carotidal aneurysm included in the study. Data regarding demographic features, clinical, laboratory and vascular imaging findings were collected. <h3>Results:</h3> A total of 39 BD patients (Male: 76.9%) with an arterial aneurysm were analyzed in this study. Mean age, mean age of diagnosis and a median follow-up of patients were 40.9±11.0 years, 29.7±7.7 and 71.8 (2-186) months, respectively. The mean age at the onset of the arterial aneurysm was 36.1±11.5 years. The median time lag between the onset of BD and detection of an aneurysm was 63.6 (0-482) months. The prevalence of male patients in BD with aneurysms, without aneurysms and only mucocutaneous were 76.9%, 52.3%, and 34.3%, respectively. Comparison of BD patients with and without an aneurysm shown in table 1. In multivariate analysis, having a venous thrombosis was the sole risk factor for the development of arterial aneurysm (OR 10.53, 95% CI 1.53-72.71) (Table). Distribution of aneurysms was shown in the figure. At the first diagnosis, a median number of the aneurysm was 1 (1-4), the median diameter of an aneurysm was 39 mm (10-80) and 16 (41%) patients had more than one aneurysm. Type of the firstly detected aneurysm was as follows; 38.5% saccular, 17.9% fusiform, 15.4% pseudoaneurysm and 2.6% dissecting aneurysms. Aneurysm type was not known in 25.6% of patients. The first diagnostic finding was an aneurysmal symptom in the 25% of BD patients. <h3>Conclusion:</h3> Aneurysm was the diagnostic symptom in 25% of BD patients with an aneurysms. The median time lag between the onset of BD and detection of an aneurysm was almost 5 years. In aneurysmal BD, there is male sex dominance and having venous thrombosis is the most important risk factor. Although pulmonary arteries have an important role in the BD course, the involvement of the aorta and iliac arteries can be seen frequently. <h3>References</h3> [1] Kalyoncu U, et al. Ann Rheum Dis 2013;72 (abs) <h3>Disclosure of Interests:</h3> Berkan Armagan: None declared, Ertuğrul Çağri Bölek: None declared, Alper Sari: None declared, Gözde Kübra Yardimci: None declared, Bayram Farisoğullari: None declared, Emre Bilgin: None declared, Fatma Gonca Eldem: None declared, Levent Kiliç: None declared, Omer Karadag: None declared, Bora Peynircioğlu: None declared, Barbaros Erhan Çil: None declared, Metin Demircin: None declared, Ali Akdoğan: None declared, Şule Apraş Bilgen: None declared, Ali İhsan Ertenli: None declared, Sedat Kiraz: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim, Speakers bureau: MSD, Abbvie, Roche, UCB, Novartis, Pfizer and Abdi Ibrahim